1. The anti-doping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology

   • Ann-Charlotte Eklöf
   • Ann-Mari Thurelius
   • Folke Sjöqvist

   Special Article 12 September 2003 Pages: 571 - 577

   

2. A preliminary report on the application of noscapine in the treatment of stroke

   • Massoud Mahmoudian
   • Massoud Mehrpour
   • Zahra Siadatpour

   Clinical Trials 27 September 2003 Pages: 579 - 581

3. Comparison of lithium concentrations in red blood cells and plasma in samples collected for TDM, acute toxicity, or acute-on-chronic toxicity

   • M. Camus
   • G. Henneré
   • R. Farinotti

   Pharmacodynamics 19 September 2003 Pages: 583 - 587

   

4. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects

   • Kazuishi Sekino
   • Takahiro Kubota
   • Tatsuji Iga

   Pharmacodynamics 19 September 2003 Pages: 589 - 592

   

5. Testing for benzodiazepine inebriation—relationship between benzodiazepine concentration and simple clinical tests for impairment in a sample of drugged drivers

   • Jørgen G. Bramness
   • Svetlana Skurtveit
   • Jørg Mørland

   Pharmacodynamics 20 September 2003 Pages: 593 - 601

6. Pharmacokinetic–pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide

   • Pedro Silveira
   • Manuel Vaz-da-Silva
   • Patrício Soares-da-Silva

   Pharmacodynamics 27 September 2003 Pages: 603 - 609

   

7. Concordance between proguanil phenotype andCYP2C19 genotype in Chinese

   • Janelle M. Hoskins
   • Gillian M. Shenfield
   • Annette S. Gross

   Pharmacogenetics 12 September 2003 Pages: 611 - 614

   

8. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers

   • Manami Oda
   • Tsutomu Kotegawa
   • Shigeyuki Nakano

   Pharmacokinetics and Disposition 27 September 2003 Pages: 615 - 619

   

9. Pharmacokinetics and metabolism of ¹⁴C-levetiracetam, a new antiepileptic agent, in healthy volunteers

   • Margherita Strolin Benedetti
   • Rhys Whomsley
   • Eugène Baltes

   Pharmacokinetics and Disposition 07 October 2003 Pages: 621 - 630

   

10. A replicate study design for testing bioequivalence: a case study on two desmopressin nasal spray preparations

    • Christian Joukhadar
    • Barbara Schenk
    • Hans-Georg Eichler

    Pharmacokinetics and Disposition 17 October 2003 Pages: 631 - 636

    

11. Changes in drug treatment in the elderly between 1971 and 2000

    • B. Lernfelt
    • O. Samuelsson
    • S. Landahl

    Pharmacoepidemiology and Prescription 16 August 2003 Pages: 637 - 644

12. "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs

    • Kathleen Bennett
    • Mary Teeling
    • John Feely

    Pharmacoepidemiology and Prescription 27 August 2003 Pages: 645 - 649

13. Exploring patient- and doctor-related variables associated with antibiotic prescribing for respiratory infections in primary care

    • Giampiero Mazzaglia
    • Achille P. Caputi
    • Claudio Cricelli

    Pharmacoepidemiology and Prescription 12 September 2003 Pages: 651 - 657

14. Statin compliance in the Umbrian population

    • Iosief Abraha
    • Alessandro Montedori
    • Carlo Romagnoli

    Pharmacoepidemiology and Prescription 24 September 2003 Pages: 659 - 661

15. Urinary tract infection in women—physician's preferences for treatment and adherence to guidelines: a national drug utilization study in a managed care setting

    • Ernesto Kahan
    • Natan R. Kahan
    • David P. Chinitz

    Pharmacoepidemiology and Prescription 27 September 2003 Pages: 663 - 668

16. Psychotropic drugs in nursing- and old-age homes: relationships between needs of care and mental health status

    • Ing-Britt Holmquist
    • Bengt Svensson
    • Peter Höglund

    Pharmacoepidemiology and Prescription 27 September 2003 Pages: 669 - 676

    

17. Prescription and non-prescription medicine use in Denmark: association with socio-economic position

    • Merete W. Nielsen
    • Ebba Holme Hansen
    • Niels Kristian Rasmussen

    Pharmacoepidemiology and Prescription 02 October 2003 Pages: 677 - 684

18. Perception of the risk of gastrointestinal adverse drug reactions with non-steroidal anti-inflammatory drugs (including coxibs): differences among general practitioners, gastroenterologists and rheumatologists

    • J. L. Montastuc
    • V. Bongard
    • M. Lapeyre-Mestre

    Pharmacoepidemiology and Prescription 11 October 2003 Pages: 685 - 688

19. Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999

    • Laurence Guédon-Moreau
    • Dominique Ducrocq
    • Jacques Caron

    Pharmacoepidemiology and Prescription 14 October 2003 Pages: 689 - 695

    

20. Error reduction: academic detailing as a method to reduce incorrect prescriptions

    • J. Shaw
    • P. Harris
    • P. S. Thomas

    Pharmacoepidemiology and Prescription 18 October 2003 Pages: 697 - 699

21. Efficacy, safety and cost of new cardiovascular drugs: a survey

    • Silvio Garattini
    • Vittorio Bertele'

    Opinion Paper 05 September 2003 Pages: 701 - 706

22. Allele and genotype frequency of CYP2C9 in Tamilnadu population

    • C. Adithan
    • N. Gerard
    • R. Krishnamoorthy

    Short Communication 19 September 2003 Pages: 707 - 709

23. The delusion of reducing sample size

    • Bernard Bégaud
    • Annie Fourrier
    • Yola Moride

    Letter to the Editors 18 October 2003 Pages: 711 - 712